Pharmacy Reimbursement • Professional Dispensing Fee • PBM Regulation • Arkansas
Arkansas’s Insurance Department reports that the $10.50 additional cost to dispense generic medications has been implemented across approximately 1,052 health benefit plans, compared with approximately 100 in October. Its report dated November 20 also identifies pending plan appeals. These figures concern Arkansas’s reimbursement framework and do not establish a nationwide payment requirement. Chad’s analysis: the expansion provides a practical example of separating drug acquisition reimbursement from payment for dispensing services, while actual entitlement and payment still require plan-specific verification.
November 20, 20261 min read
Read the analysisLouisiana • Pharmacy Records • Pharmacy Compliance • Controlled Substances
Louisiana’s pharmacy rule changes took effect November 20, according to the Board’s regulatory-project record. The published text expressly requires searches by patient, prescriber, drug and dispensing date, with immediate printed and downloadable electronic retrieval. It also allows date-sequence filing and revises identification and imaging provisions. The two-year retention obligation already existed. Chad’s analysis: pharmacies should test their software and record-production procedures against the revised language, while preserving applicable federal controlled-substance requirements.
November 20, 20262 min read
Read the analysisOpioid Litigation • Controlled Substances • West Virginia • Pharmacy Compliance
Law360 reports that Judge David Faber again ruled for three opioid distributors on November 18 after the Fourth Circuit vacated their earlier victory. The report describes a failure to prove diversion while the drugs were under the distributors’ control. The appellate court previously allowed West Virginia public-nuisance claims and money-funded abatement to proceed. This article distinguishes the reported outcome from the reviewed appellate record. The new district opinion and any separate judgment remain unreviewed.
November 19, 20262 min read
Read the analysisHIPAA • Privacy • Pharmacy Compliance • Patient Access
HHS published its final HIPAA Privacy Rule changes November 19. HIPAA-covered pharmacies will face a 15-calendar-day records-access standard, revised copy-fee requirements and updated privacy notices. The rule also removes the effort to obtain written acknowledgment of notice receipt. The published effective date is January 19, 2027, with general compliance due July 19, 2027. Chad’s analysis: pharmacy leaders should use the transition to align request handling, patient communications and vendor responsibilities.
November 19, 20261 min read
Read the analysisPBM Regulation • Texas • Pharmacy Ownership • Contracting
Texas H.B. 1236, filed November 18, would prohibit PBM control or common control of Texas-licensed pharmacies. The proposal reaches ownership and specified contractual arrangements, with license consequences and conditional temporary authorizations. Its operational prohibition would apply January 1, 2028, if enacted. Filing changes no current obligation. Chad’s analysis: the practical question is how the proposed control test would distinguish routine contracting from influence over pharmacy practice. The Board’s implementing criteria would be consequential.
November 19, 20261 min read
Read the analysisPharmacist Services • Reimbursement • Tennessee • Patient Access
UnitedHealthcare and CPESN announced November 18 that their care model is available to Community Plan members in seven states, including Tennessee. Participating independent pharmacies connect patients with clinical support, selected testing and virtual visits. CPESN says the model supports reimbursement for pharmacists’ clinical care. The announcement does not disclose payment rates or contracting terms. Chad’s analysis: the opportunity deserves review, with service revenue evaluated alongside the resources required to deliver care.
November 19, 20261 min read
Read the analysisFDA • Drug Quality • Supply Chain • Pharmacy Operations
FDA announced its Enhanced Approach for Sampling and Testing on November 18. The agency plans to test drug samples from retail pharmacies and wholesale distributors, using modern screening and traditional methods to assess identity, purity, and potency. Results will guide inspection priorities and possible regulatory action. FDA announced no new pharmacy testing requirement or compliance deadline. Chad’s analysis: pharmacies can review how they retrieve supplier and lot information and handle quality complaints.
November 18, 20261 min read
Read the analysisCompounding • GLP-1 • Advertising • Pharmacy Litigation
A Florida federal magistrate judge recommended that Novo Nordisk prevail on liability against MD Exam over advertising for compounded semaglutide. The November 13 report addresses use of the Ozempic and Wegovy marks, including “oral Ozempic” and a “Wegovy Program.” The recommendation leaves remedies for further proceedings. For pharmacies and telehealth partners, the case offers a concrete reason to review how marketing identifies a compounded product and describes its relationship to an FDA-approved medicine.
November 18, 20261 min read
Read the analysisConscience Protections • Pharmacy Litigation • Scope of Practice • Patient Access
An Illinois lawsuit brings a pharmacist’s religious objection to aid-in-dying referrals before a federal court. The plaintiffs include Luke Vander Bleek and Fitzgerald Pharmacy. An agreed September order provided temporary protection for specified parties and providers while preserving enforcement against nonparties. The dispute highlights a practical question for pharmacy policies: which information, referral, or records duties may remain when a professional declines participation? The answer requires checking the applicable state law, professional role, and scope of any court order.
November 18, 20262 min read
Read the analysisFDA • REMS • Pharmacy Operations • Isotretinoin
The iPLEDGE program lists November 15 as the effective date for revised isotretinoin requirements. Under its updated instructions, pharmacists enter the prescriber’s National Provider Identifier to obtain authorization for patients who cannot get pregnant. The program no longer assigns a dispense-by date for that group. The seven-day pickup window continues for patients who can get pregnant. A patient who misses the first window needs a repeat pregnancy test in a medical setting before starting treatment, and the additional waiting period has ended.
November 16, 20261 min read
Read the analysisFDA • Infusion Pharmacy • Nephrology • Drug Safety
FDA has approved Gazyva, or obinutuzumab, as the first specifically approved treatment to induce proteinuria remission in adults with primary membranous nephropathy who are at risk of progression. Genentech announced the approval November 15. In the trial FDA reviewed, complete remission at 104 weeks was 36% with Gazyva and 6% with tacrolimus. Infusion pharmacists can verify that order sets reflect the kidney indication, including its dosing schedule, hepatitis B screening, and precautions for infusion reactions.
November 16, 20261 min read
Read the analysisPharmacy Compliance • Health Care Fraud • Medicare • Medicaid • Florida
Federal prosecutors said November 12 that Jacksonville pharmacist Albert Chester agreed to plead guilty in a case involving HIV post-exposure prophylaxis prescriptions. The Justice Department describes an alleged $51 million scheme involving payments to marketers when referred prescriptions generated paid insurance claims. Prosecutors also allege that prescriptions were authorized without patient evaluations and claims used unsupported diagnosis codes. The case gives pharmacy owners a reason to review how referrals become prescriptions and how diagnoses supplied with claims are verified.
Updated November 13, 20261 min read
Read the analysisAlabama • Pharmacy Licensure • Pharmacy Technicians • Military Families
The Alabama State Board of Pharmacy proposes a formal, fee-free initial application process for qualified pharmacists and pharmacy technicians who relocate under military orders as servicemembers or their spouses. Eligible applicants would need a qualifying license in good standing and documentation of the move. The Board’s executive secretary would issue licenses on completed applications without a separate Board vote. Written comments are due by close of business November 17, and the Board will hold a public hearing November 18 at 9 a.m. Central in Birmingham.
Updated November 13, 20261 min read
Read the analysisFTC • Health Privacy • Telehealth • Pharmacy Fulfillment • Consumer Protection
The FTC filed an amended complaint November 10 in federal court in Northern California. Arizona, Florida, Nebraska, Ohio, and Wisconsin joined the existing plaintiffs and added claims under their consumer protection laws. The case alleges that Hims & Hers shared sensitive information about treatment interests with advertising platforms and misled consumers about prescription charges and cancellation. The allegations remain pending. Pharmacies that fulfill prescriptions for online platforms can review what their partners disclose at intake, when payment is authorized, and which vendors receive patient information.
November 11, 20262 min read
Read the analysisFDA • GLP-1 • Drug Safety • Vision Loss • Pharmacy Counseling
FDA is requiring a class-wide GLP-1 labeling warning for a possible increase in nonarteritic anterior ischemic optic neuropathy, a rare condition that can permanently impair vision. FDA’s pooled trials found 6.4 cases per 100,000 person-years with GLP-1 therapy versus 3.8 in comparison groups. Reduced blood flow injures the optic nerve, but how these drugs might contribute remains uncertain. The evidence cannot yet identify who should switch or which drug would lower that risk. FDA advises immediate reporting of sudden vision changes in one eye and prompt ophthalmology referral when NAION is suspected.
November 10, 20262 min read
Read the analysisDEA • Controlled Substances • Drug Supply • Pharmacy Operations
DEA’s final order took effect November 10 when it appeared in the Federal Register. It raises the national production quotas for two amphetamine categories, hydromorphone, and methylphenidate for sale. The published figures match the order made available for public inspection on November 9. DEA separately published proposed 2027 quotas, with comments due December 10 at 11:59 p.m. Eastern for electronic filings. The higher 2026 limits allow additional production. Pharmacy teams can track whether availability improves by strength, package, and supplier.
November 10, 20261 min read
Read the analysisNorth Carolina • Scope of Practice • Collaborative Practice • Pharmacy Operations
North Carolina’s pharmacy and medical boards scheduled a joint hearing for November 10 on rules for clinical pharmacist practitioners. The proposals implement a 2025 law that expanded physician-delegated services and authorized site-specific agreements for institutions and group practices. The drafts specify required agreement terms and would set annual practice-relevant continuing education at 25 hours. Written comments are due December 14, and the boards list April 1, 2027, as the proposed effective date. Practices can use the comment period to flag provisions that may be difficult to implement.
November 10, 20261 min read
Read the analysisPBM • Medicare Part D • Reimbursement • Contracting
CMS published a correction on November 9 directing electronic comments on its Medicare Part D PBM proposal to docket CMS-2026-3533. The October 20 notice listed CMS-2026-2533. Comments remain due December 15, 2026, at 5 p.m. Eastern Standard Time. The correction concerns where to file. The compensation, reporting, and sponsor oversight provisions remain proposed. Pharmacies preparing comments can use the corrected docket and save the submission confirmation with their comment materials.
Updated November 9, 20261 min read
Read the analysisCompounding • GLP-1 • Consumer Protection • Litigation
A newly accessible October 30 complaint in New Jersey federal court alleges that two Empower entities misled consumers about the clinical evidence, personalization, and quality of compounded semaglutide and tirzepatide. The plaintiffs bring state-law claims and seek class certification, corrective advertising, and monetary relief. The complaint states the plaintiffs’ allegations. Both defendants filed waivers of service November 6, and the public docket lists January 4, 2027, as their answer deadline. The filing gives pharmacy and telehealth teams a reason to review whether their marketing claims describe the formulation patients actually receive.
November 9, 20261 min read
Read the analysisMedicare Part D • Reimbursement • Network Access • Patient Access • Professional Dispensing Fee
MedPAC staff presented preliminary findings from the commission’s first pharmacist focus groups on November 6. Participants described how reimbursement affected stocking decisions, how prior authorization delayed some fills, and how preferred-network status shaped what patients paid. The small, qualitative study describes participant experiences. Those accounts give practical context to a question Chad Frost and Asher Jackson Frost examine in their commentary accepted by the Journal of the American Pharmacists Association. Does the professional dispensing fee reflect the work needed to dispense a prescription safely?
November 9, 20262 min read
Read the analysisPBM • Pharmacy Contracting • Network Access • Reimbursement • Competition
CVS Health announced on November 4 that it plans to create two public companies, targeting the first half of 2028. The standalone CVS Pharmacy would include retail and mail pharmacy, MinuteClinic, and Health100. Aetna, CVS Caremark, CVS Specialty, Oak Street Health, and Signify Health would stay together. CVS says it will continue operating as it does today until closing. For pharmacy operators, the next details to watch are how the companies contract with each other and whether any network or reimbursement terms change.
November 4, 20262 min read
Read the analysisPBM • Antitrust • Reimbursement • Florida • Litigation
Express Scripts filed a notice of removal on November 2 in Florida’s reimbursement case against the company and Prime Therapeutics. Florida alleges the PBMs’ 2019 agreement suppressed retail pharmacy reimbursement. Express Scripts denies the allegations and argues that the challenged network serves both commercial clients and federal programs, including TRICARE. The filing changes where the case is being litigated while jurisdiction remains open to challenge. It creates no immediate reimbursement change for Florida pharmacies.
November 4, 20261 min read
Read the analysisDEA • Controlled Substances • Registration • Pharmacy Operations
DEA’s final technical amendment, published and effective November 4, expressly applies its application withdrawal provision to registration renewals. After DEA accepts an application for filing, it treats the application as withdrawn if the applicant or registrant asks for it back or fails to respond to official correspondence sent by registered or certified mail with return receipt requested. DEA says it already applied the rule to renewals. Pharmacy operators can use the clarification to check who receives, logs, and responds to renewal correspondence.
November 4, 20261 min read
Read the analysis340B • Contract Pharmacy • Patient Access • Reimbursement
Johnson & Johnson’s September 4 notice sets November 3 as the start date for its contract pharmacy designation policy for affected 340B grantees. The manufacturer generally allows one registered dispensing location within 40 miles of the grantee site, with a separate designation for certain pulmonary arterial hypertension drugs. AIDS Drug Assistance Programs are excluded, and applicable state exceptions are communicated separately. Grantees and their pharmacy partners should verify that the correct dispensing site is active before assuming replenishment will qualify for 340B pricing.
November 3, 20261 min read
Read the analysisPBM • ERISA • Pharmacy Reimbursement • Transparency • Audit Rights
DOL’s final PBM disclosure rule was published November 2, establishing January 4, 2027 as its effective date. The detailed requirements apply to plan years beginning on or after July 1, 2027. Covered large self-insured ERISA plans gain compensation disclosures and audit rights. Pharmacy leaders should use the confirmed dates to plan contract reviews while distinguishing a plan’s oversight rights from a pharmacy’s own reimbursement and recoupment remedies.
Updated November 2, 20262 min read
Read the analysisCompounding • FDA • Drug Safety • Recalls • Pharmacy Operations
FDA posted and classified an ongoing voluntary recall involving Victory Medical Center Pharmacy on October 30. The Austin pharmacy initiated the action October 19. FDA identifies 42 Class II product entries and distribution in Colorado, Florida, and Texas, with lack of processing controls as the stated reason. The records include compounded semaglutide and tirzepatide combinations, peptides, and vitamin preparations. Pharmacies and receiving practices should match the specific product and lot records before acting, rather than treating every preparation from the facility as recalled.
November 2, 20262 min read
Read the analysisPBM • Maryland • Specialty Pharmacy • Reimbursement • Public Comments
Maryland’s insurance and health agencies presented a draft final PBM workgroup report October 30 and are accepting written comments through the end of November 13. The draft recommends studying pharmacy-benefit delivery models, revising specialty-drug and specialty-pharmacy definitions, and publishing specialty-drug lists. It does not adopt new reimbursement rates or impose new pharmacy duties. Pharmacy leaders can use the comment period to address accreditation, network access, and how specialty classifications affect dispensing.
November 2, 20261 min read
Read the analysisControlled Substances • DEA • ADHD • Clinical Pharmacology • Pharmacy Operations
Simtriyo, the brand for centanafadine extended-release capsules, is indicated for ADHD in adults and children aged six years and older weighing at least 20 kg. DEA’s Schedule III rule took effect October 30. Its current fit in therapy may center on patients who might benefit from its combined reuptake activity, an assessment requiring clinical judgment rather than an established responder subgroup. Pharmacists should understand the labeled mechanism, safety information, and controlled-substance handling requirements.
October 30, 20262 min read
Read the analysisCompounding • Peptides • 503A • FDA • Compliance
HHS’s peptide policy notice was published October 30, making November 13 the end of its two-week comment period. The published notice still calls the underlying policy a draft and states that it is nonbinding. Publication does not establish FDA approval or add the six substances to the final 503A bulks list. This update confirms the public-comment timing while preserving the status qualifications, identity and route limits, and operating conditions described in the earlier analysis.
Updated October 30, 20263 min read
Read the analysisMedicare Part B • Pharmacy Compliance • Drug Billing • HHS OIG
A new HHS OIG data brief identifies gaps in Medicare’s oversight of hospital outpatient drug billing. The review flagged 160,918 claim lines with mismatched drug and procedure codes, but did not establish that their $27.6 million in payments were improper. A nonstatistical sample confirmed coding errors. The findings give hospital pharmacy and billing teams a concrete reason to review drug-code mappings and claim controls, without creating a new regulatory requirement.
October 30, 20261 min read
Read the analysisMedicare • Pharmacy Quality • Medication Adherence • Administrative Law • Pharmacy Litigation
CVS Health and its insurer subsidiaries sued HHS and CMS October 26 over the 2027 Medicare Star Ratings. Their complaint challenges the adoption of 28 criteria and the statutory basis for data used in 12. It also questions whether claims-based medication adherence reflects clinical care accurately. CVS projects more than $2 billion in affected 2028 payments. These are litigating positions and estimates. Pharmacy leaders should examine the dispute’s implications for data quality, transparent methods, and review procedures.
October 28, 20262 min read
Read the analysis340B • Pharmacy Litigation • Massachusetts • Data Privacy • Patient Access
Five Massachusetts hospitals sued Eli Lilly October 27 over claims data requirements tied to 340B pricing. According to their complaint, Lilly withheld discounts after they declined to submit in-house pharmacy and medical claims through 340B ESP. The hospitals assert Massachusetts consumer-protection and unjust-enrichment claims and seek injunctions and monetary relief. These are allegations, not findings. Pharmacy leaders should review purchasing exposure and data-sharing controls. Later docket orders were not verified for this report.
October 28, 20262 min read
Read the analysis340B • Supreme Court • Mississippi • Contract Pharmacy • State Regulation
On October 27, the Supreme Court requested Mississippi’s response in Novartis v. Fitch, a pending challenge to the state’s 340B contract pharmacy law. The deadline is November 27, 2026. Fitch had waived a response on October 20. Novartis argues that federal law preempts the state’s requirements. The new docket entry advances briefing without granting review, a stay, or other relief. The company’s request for Supreme Court consideration remains pending.
October 28, 20261 min read
Read the analysisWisconsin • Medicaid • Prior Authorization • Patient Access • Pharmacy Operations
Wisconsin’s November preferred drug list moves generic buprenorphine patches to non-preferred status, requiring prior authorization, while Butrans remains preferred. The October list temporarily preferred the generic because of Butrans shortage and access issues. The new list takes effect November 1 for Wisconsin Medicaid, BadgerCare Plus Standard, and SeniorCare. Pharmacies should review affected prescriptions and authorization needs before the change. The reviewed documents do not specify how existing approvals will transition.
October 27, 20261 min read
Read the analysisCompliance • Medicare and Medicaid • Exclusion Screening • OIG
OIG’s October 27 FAQ update says its exclusion list currently contains only OIG actions, while publication arrangements with CMS remain under development. OIG also confirms its continuing role in resolving exclusion exposure in False Claims Act matters. The guidance follows an October 14 delegation notice. Pharmacy compliance leaders should review screening assumptions and escalation procedures without treating the FAQ as a new screening mandate.
October 27, 20261 min read
Read the analysisPBM • Pharmacy Audits • Congressional Oversight • Enterprise Risk
House Oversight Chairman James Comer requested records from CVS Caremark, Express Scripts, and Optum Rx on October 23 concerning possible retaliation against independent pharmacies that supported H.R. 6610. The letters seek audit-selection methods, provider agreements, audit totals, and detailed records for three states. Requested briefings are due October 30 and documents November 6. These requests are directed to the PBMs. The inquiry does not decide whether retaliation occurred. Pharmacy leaders can use the development to review how they document notices, deadlines, communications, and outcomes.
October 26, 20261 min read
Read the analysisSouth Carolina • Compounding • Collaborative Practice • Compliance
South Carolina’s Board of Pharmacy published proposed compounding and collaborative-practice rules October 23. The package addresses sterile and hazardous-drug preparation and changes facility-permit training language. Comments are due November 23 at 5 p.m. A December 11 hearing depends on a timely qualifying request. These proposals are not effective. Pharmacy leaders should review current procedures and agreements before preparing their comments.
October 26, 20261 min read
Read the analysisCalifornia • Pharmacy Regulation • Scope of Practice • Compliance
California opened comments October 23 on proposed rules addressing self-assessments and the statutory standard-of-care model. The Board would repeal duplicative provisions and specified prescriptive furnishing protocols, and explains that self-assessment duties remain in statute. Comments are due December 7. No hearing is scheduled. The proposal follows legislation effective January 1, 2026. Pharmacy leaders should compare the draft with current procedures and distinguish this regulatory cleanup from the earlier statutory change.
October 26, 20261 min read
Read the analysisAlabama • Pharmacy Regulation • Compliance • Enterprise Risk
Alabama’s revised pharmacy civil-penalty rule and category-specific schedules took effect October 15, 2026, according to the Board of Pharmacy. The framework uses an advisory calculation based on misconduct, public-health risk, and compliance history, with discretion bounded by the applicable schedule. It does not impose an automatic fine. Pharmacy leaders should review their category’s exposure and preserve records supporting compliance, remediation, and the circumstances of any alleged violation.
October 22, 20261 min read
Read the analysisDrug safety • Counterfeit medicines • Pharmacy operations
FDA’s October 16 alert identifies counterfeit over-the-counter eye drops found in Florida and Georgia, with possible distribution elsewhere. Testing found bacterial contamination in two products, although the agency reports no associated adverse events. The warning supports immediate patient counseling and review of suspicious retail stock. FDA provides packaging comparisons and advises retailers to contact the company named on the label. A separate September recall concerns a different issue.
October 22, 20261 min read
Read the analysisCompounding • Recalls • Veterinary pharmacy • Quality systems
Wedgewood Pharmacy announced a nationwide recall of certain compounded veterinary medications on October 21 after identifying unreliable laboratory testing that could allow potency errors. The FDA-hosted notice directs pharmacies to check inventory, quarantine affected stock and notify customers who received it. Product and lot verification should guide the response. Animal owners with matching preparations should stop use, retain the medication and contact recall services.
October 22, 20261 min read
Read the analysisGeorgia • Prescription Transfers • Controlled Substances • Pharmacy Technicians
Georgia’s Board of Pharmacy has proposed changes to prescription transfers and pharmacy-technician continuing education. Its October notice would consolidate transfer requirements, recognize qualifying transfers of unfilled electronic Schedule II prescriptions, and remove general technician CE while retaining function-specific statutory requirements. These changes are not effective. Written comments must arrive before November 17, 2026, ahead of a November 18 hearing and consideration for adoption.
October 22, 20261 min read
Read the analysisControlled Substances • Pharmacy Operations • Compliance
The expedited federal rule made controls effective August 27. Handlers must align registration, inventory, records, security, and prescribing.
Updated October 21, 20264 min read
Read the analysisTelemedicine • Controlled Substances • Compliance
OMB is reviewing the final special-registration rule while the temporary prescribing flexibilities approach their December 31 expiration.
Updated October 21, 20264 min read
Read the analysis340B • Reimbursement • Compliance
Approved manufacturer plans target a January 2027 start while a new hospital challenge contests the revised 340B rebate pilot.
Updated October 21, 20266 min read
Read the analysisCompounding • Peptides • FDA
An FDA advisory committee recommendation is a policy signal, not legal authority to compound a bulk drug substance.
Updated October 21, 20263 min read
Read the analysisMedical Marijuana • Federal Regulation • Controlled Substances
The April rescheduling rule created a federal pathway for specified medical marijuana activity. It did not legalize recreational distribution or use.
September 14, 20263 min read
Read the analysisPBM • Audit • Reimbursement
Why PBM audit response requires coordinated legal, operational, reimbursement, compliance, and data judgment from the first notice forward.
August 4, 20263 min read
Read the analysisMedicare Advantage • False Claims Act • Compliance
Three August settlements show how unsupported diagnoses, retrospective reviews, and risk-sharing payments can expose provider groups to False Claims Act scrutiny.
September 1, 20264 min read
Read the analysisCompounding • GLP-1 • Compliance
Federal law separates patient-specific preparation, shortage-era copies, and drugs made from ingredients that remain ineligible for compounding.
August 21, 20264 min read
Read the analysisFTC Enforcement • PBM • Contracting
The proposed PBM orders offer pharmacies, plan sponsors, lawmakers, and future litigants a practical template for less restrictive commercial terms.
August 21, 20264 min read
Read the analysisAntitrust • FTC Enforcement • PBM
The FTC’s proposed Express Scripts and Caremark orders reshape pharmacy benefit contracting while leaving its standalone Section 5 theory unresolved.
August 7, 20265 min read
Read the analysisAntitrust • Algorithmic Pricing • Pharmacy
Two pharmacy reimbursement lawsuits test whether a shared pricing platform or a direct PBM agreement can satisfy Section 1 of the Sherman Act.
August 7, 20265 min read
Read the analysisContracting • Leadership • Operations
Pharmacy leaders translate contract language into credentialing, claims, documentation, escalation, and accountability before the first dispute arrives.
August 4, 20263 min read
Read the analysis